CONFORMED COPY

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1933

~~March~~April 111, 2009

Pharmaxis Ltd

2/10 Rodborough Road,
Frenchs Forest, NSW 2086
Australia

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F þ Form 40-F o

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes o No þ

(If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .)

ASX/NASDAQ Media Release 111 ~~March~~April 2009

Pharmaxis ~~appoints~~Announces ~~French~~Milestone ~~Distributor~~in Phase III Trial for ~~Aridol™~~Cystic Fibrosis

Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ: PXSL) istoday ~~pleased~~announced tocompletion ~~announce~~of ~~that~~the ~~it has appointed Praxis~~first ~~Pharmaceutical~~component ~~France~~of ~~SARL as~~ its ~~French~~Phase ~~marketer~~III ~~and~~international ~~distributer~~trial ~~for~~assessing the ~~asthma~~effectiveness ~~diagnostic~~of ~~tool,~~Bronchitol in people ~~Aridol~~with cystic fibrosis.

~~Praxis~~The ~~Pharmaceutical~~final issubject ahas ~~recently~~now ~~established~~completed ~~company~~their ~~created~~final toclinical ~~introduce~~visit aand ~~portfolio of respiratory specialist products into~~ the ~~French~~trial ~~pharmaceutical~~has ~~market.~~run ~~Praxis~~to ~~will~~time ~~complete the~~and ~~reimbursement~~budget. ~~application~~The ~~for~~first ~~Aridol~~subject inentered ~~France and thereafter market~~ the ~~product~~trial toin ~~hospital specialists~~April 2007.

DrThe ~~Alan~~trial ~~Robertson,~~was ~~Pharmaxis~~conducted ~~CEO~~in ~~said~~40 ~~“We~~centres ~~are~~in ~~delighted~~four todifferent ~~announce~~countries ~~this agreement~~ and ~~are~~involved ~~looking~~325 randomized ~~forward~~subjects ~~to working~~ with ~~Praxis~~cystic onfibrosis. ~~developing~~The ~~the~~trial ~~French~~was ~~market~~a ~~for~~double ~~Aridol.~~blind, ~~Aridol~~placebo iscontrolled astudy ~~precisely~~designed ~~engineered~~with ~~test~~the ~~that~~assistance weof ~~believe~~the ~~will~~European beregulatory anagency ~~improvement~~(EMEA) and onwith ~~current~~the ~~practice.~~objective ~~Aridol~~of ~~improves~~seeking ~~the~~a ~~identification~~marketing ofapproval ~~bronchial~~for ~~hyperresponsiveness~~Bronchitol ~~which~~for istreating ~~one~~cystic offibrosis ~~the~~in ~~hallmarks~~Europe ofand ~~asthma~~elsewhere.”

The ~~total~~results ~~population~~of ~~affected~~the bytrial ~~Asthma~~are inexpected ~~France~~to isbe ~~approximately~~available ~~3.1 million.~~later ~~The~~this ~~French bronchial~~month ~~challenge~~after ~~testing~~data ~~market~~review ~~is dominated by methacholine~~ and statistical ~~more~~analysis ~~than~~of ~~25,000~~the ~~tests~~various ~~are conducted~~endpoints ~~annually~~have ~~with~~been ~~little~~completed. ~~recent~~The ~~innovation~~first inobjective of the trial ~~field.~~is ~~Aridol’s ability~~ to ~~detect~~demonstrate ~~airway hyperresponsiveness~~an improvement in ~~poorly~~lung ~~controlled~~function. ~~asthmatics~~Consistent ~~offers~~loss ~~information~~of tolung ~~the~~function ~~respiratory~~is ~~physician~~the ~~that~~leading ~~has~~cause ~~previously~~of ~~not~~death ~~been~~of ~~available~~people with cystic fibrosis.

~~Aridol~~Dr isAlan ~~approved~~Robertson, ~~for~~Pharmaxis ~~sale~~Chief inExecutive ~~most~~Officer ~~major~~said: ~~European~~“We ~~countries,~~are ~~Australia~~very ~~and~~pleased ~~Korea.~~to ~~Aridol~~announce ~~has been~~this ~~included~~major inmilestone ~~the~~for ~~Global~~Pharmaxis ~~Initiative~~and ~~for~~look ~~Asthma~~forward ~~guidelines,~~to ~~and~~the inresults of the ~~U.S.~~study ~~Asthma~~with ~~Management Guidelines~~great interest. It is ~~one~~hoped ofBronchitol ~~the~~will ~~tests~~change ~~recommended~~the bytherapeutic ~~the~~landscape ~~World~~for ~~Anti-Doping~~people ~~Agency,~~living ~~and~~with ~~other~~cystic ~~sports~~fibrosis ~~governing~~and ~~bodies~~provide toa ~~ensure~~new ~~elite~~therapeutic ~~athletes~~regimen ~~who~~that ~~are~~helps ~~asthmatic~~to ~~are~~prolong ~~properly diagnosed and treated~~life.”

The second component of the trial will examine the safety of Bronchitol in people with cystic fibrosis.

Pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Bronchitol in cystic fibrosis.

Bronchitol is designed to hydrate the airway surface of the lungs, and promote normal lung mucus clearance in order to improve lung function, break the cycle of repeated respiratory infections and blockages, and improve quality of life for patients with CF. Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.

A second Phase III clinical trial is actively recruiting in centres across the USA, Canada, Argentina, Germany, Belgium and France. This second trial has been designed with the assistance of the FDA through its Special Protocol Assessment Scheme and is the second of two trials required by the FDA before Bronchitol is considered for marketing in the USA.

#ends#

Page 1 of 2

SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson — Chief Executive Officer
Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:
Australia:
Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

United States:
Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

~~Page 1 of 2~~www.pharmaxis.com.au

Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the “Risk Factors and Other Uncertainties” section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

Page 2 of 2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Pharmaxis Ltd(Registrant)
	Pharmaxis Ltd (Registrant)
Date: March 11, 2009	By:	/s/ David McGarvey
Date: April 1, 2009	By:	/s/ David McGarvey
		Name:	David McGarvey
		Title:	Chief Financial Officer

Filing Compare · Pharmaxis Ltd.